Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: Implications of imatinib mesylate

World Journal of Gastroenterology

Volumn 12, Issue 23, 2006, Pages 3760-3765

  Yeh, Chun Nan ^a   Chen, Tsung Wen ^a   Wu, Ting Jung ^a   Hsueh, Swei ^a   Jan, Yi Yin ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Gastrointestinal stromal tumor; Glivec; Kit gene mutation; Patient survival

Indexed keywords

IMATINIB; MUTANT PROTEIN; PLATELET DERIVED GROWTH FACTOR A;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASIAN; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; INTERMETHOD COMPARISON; INTESTINE SURGERY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SMALL INTESTINE TUMOR; STATISTICAL SIGNIFICANCE; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 33745450900     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i23.3760     Document Type: Article

References (26)

1. Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl Surg 1996; 33: 817-872
2. Mocellin S, Provenzano M, Lise M, Nitti D, Rossi CR. Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-alpha to patients with soft tissue limb sarcoma. Int J Cancer 2003; 107: 317-322
3. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58
4. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-1269
5. Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23: 377-389
6. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056
7. Akwari OE, Dozois RR, Weiland LH, Beahrs OH. Leiomyosarcoma of the small and large bowel. Cancer 1978; 42: 1375-1384
8. Shiu MH, Farr GH, Papachristou DN, Hajdu SI. Myosarcomas of the stomach: natural history, prognostic factors and management. Cancer 1982; 49: 177-187
9. McGrath PC, Neifeld JP, Lawrence W Jr, Kay S, Horsley JS 3rd, Parker GA. Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg 1987; 206: 706-710
10. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215: 68-77
11. Goss GA, Merriam P, Manola. Clinical and pathological characteristics of gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol 2000; 19: 559
12. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566
13. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145
14. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Ziger AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925-932
15. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000; 19: 3321-3528
16. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480
17. Green S, Weiss GR. Southwest Oncology Group standard response criteria, end point definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-253
18. Cancer Therapy Evaluation Program. Common toxicity criteria manual: common toxicity criteria, version 2.0. Bethesda, MD. National Cancer Institute, 1999
19. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349
20. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999; 30:1213-1220
21. Ludwig DJ, Traverso LW. Gut stromal tumors and their clinical behavior. Am J Surg 1997; 173: 390-394
22. Lehnert T. Gastrointestinal sarcoma (GIST)- a review of surgical management. Ann Chir Gynaecol 1998; 87: 297-305
23. Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumors. Br J Surg 2003; 90: 332-339
24. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Scuba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001; 136: 383-389
25. Plaat BE, Hollema H, Molenaar WM, Torn Broers GH, Pijpe J, Mastik MF, Hoekstra HJ, van den Berg E, Scheper RJ, van der Graaf WT. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18: 3211-3220
26. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA. Pdgfra activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710